(ARVN) Arvinas - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04335A1051

ARVN: Protein, Degraders, Cancer, Breast, Prostate

Arvinas, Inc. is a clinical-stage biotech company pioneering a novel approach to treating diseases by targeting and degrading proteins that cause harm. Their platform centers around PROTACs—proteolysis-targeting chimeras—which hijack the cells natural protein disposal system to eliminate disease-causing proteins. This is a significant shift from traditional drug development, which often focuses on inhibiting or blocking proteins rather than removing them entirely.

Their pipeline is focused on cancer, with three lead programs. Bavdegalutamide and ARV-766 are oral PROTACs targeting metastatic castration-resistant prostate cancer, a condition where prostate cancer grows despite hormone therapies. Both are in Phase 1/2 trials, aiming to show safety and efficacy. ARV-471 is further along, in Phase 3 trials, for estrogen receptor-positive breast cancer. This drug targets the estrogen receptor, a key driver in many breast cancers.

Collaborations are a key part of their strategy. Partnerships with pharma giants like Pfizer, Genentech, Roche, Bayer, and Carrick Therapeutics provide validation and resources. These deals not only bring in capital but also leverage the expertise and infrastructure of larger companies, reducing some of the risks in drug development.

As a public company on NASDAQ (ticker: ARVN), Arvinas has a market cap of ~$1.28 billion. Their financials reflect a typical clinical-stage biotech: no earnings yet, with a forward P/E of 17.7 and a price-to-book ratio of 2.19. The price-to-sales ratio is 7.98, reflecting the premium investors place on their pipeline and technology. Founded in 2013 and based in New Haven, Connecticut, Arvinas is at the forefront of the PROTAC revolution in drug discovery.

Additional Sources for ARVN Stock

ARVN Stock Overview

Market Cap in USD 1,242m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2018-09-27

ARVN Stock Ratings

Growth 5y -77.0%
Fundamental -31.1%
Dividend 0.0%
Rel. Strength Industry -81.3
Analysts 4.59/5
Fair Price Momentum 7.09 USD
Fair Price DCF -

ARVN Dividends

No Dividends Paid

ARVN Growth Ratios

Growth Correlation 3m -67.8%
Growth Correlation 12m -87.5%
Growth Correlation 5y -52.9%
CAGR 5y -23.85%
CAGR/Max DD 5y -0.26
Sharpe Ratio 12m -1.31
Alpha -95.86
Beta 1.62
Volatility 210.25%
Current Volume 2202.4k
Average Volume 20d 1500.2k
What is the price of ARVN stocks?
As of March 15, 2025, the stock is trading at USD 8.43 with a total of 2,202,370 shares traded.
Over the past week, the price has changed by -53.88%, over one month by -53.96%, over three months by -55.61% and over the past year by -81.15%.
Is Arvinas a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Arvinas (NASDAQ:ARVN) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -31.05 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARVN as of March 2025 is 7.09. This means that ARVN is currently overvalued and has a potential downside of -15.9%.
Is ARVN a buy, sell or hold?
Arvinas has received a consensus analysts rating of 4.59. Therefor, it is recommend to buy ARVN.
  • Strong Buy: 15
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ARVN stock price target?
According to ValueRays Forecast Model, ARVN Arvinas will be worth about 7.9 in March 2026. The stock is currently trading at 8.43. This means that the stock has a potential downside of -6.52%.
Issuer Forecast Upside
Wallstreet Target Price 60.7 620%
Analysts Target Price 63.4 652.3%
ValueRay Target Price 7.9 -6.5%